Advancements in the care of premature babies are leading to improved survival rates. However, the incidence of neonatal diseases with life-long consequences such as bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) is increasing. A novel study has implicated granulocyte colony-stimulating factor (G-CSF) in both BPD and ROP, making it a promising therapeutic candidate.
